|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM320557138 |
| 003 |
DE-627 |
| 005 |
20250228202424.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2021.108680
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1068.xml
|
| 035 |
|
|
|a (DE-627)NLM320557138
|
| 035 |
|
|
|a (NLM)33493672
|
| 035 |
|
|
|a (PII)S1521-6616(21)00017-6
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Koga, Tomohiro
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Current insights and future prospects for the pathogenesis and treatment for rheumatoid arthritis
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 11.06.2021
|
| 500 |
|
|
|a Date Revised 11.06.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2021 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Genetic, environmental, and epigenetic factors simultaneously or serially contribute to immune cells and resident joint tissue cell abnormalities, invariably leading to joint destruction. Understanding the immune cell dysfunction in earlier years has brought forward life-changing therapeutics to patients with rheumatoid arthritis (RA). Further advances in the understanding of the immune and joint tissue-resident cell signaling and metabolic defects should produce additional tools to treat people with RA and foretell those who will respond to each biological or small drug. This review presents the latest evidence on RA pathogenesis and outlines the prospects for achieving precision medicine
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a Anticitrullinated peptide antibodies
|
| 650 |
|
4 |
|a Biological disease-modifying antirheumatic drugs (bDMARDs)
|
| 650 |
|
4 |
|a Cytokines
|
| 650 |
|
4 |
|a Immune responses
|
| 650 |
|
4 |
|a Rheumatoid arthritis
|
| 650 |
|
7 |
|a Anti-Citrullinated Protein Antibodies
|2 NLM
|
| 650 |
|
7 |
|a Antirheumatic Agents
|2 NLM
|
| 650 |
|
7 |
|a Biological Products
|2 NLM
|
| 650 |
|
7 |
|a Cytokines
|2 NLM
|
| 700 |
1 |
|
|a Kawakami, Atsushi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tsokos, George C
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 225(2021) vom: 01. Apr., Seite 108680
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:225
|g year:2021
|g day:01
|g month:04
|g pages:108680
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2021.108680
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 225
|j 2021
|b 01
|c 04
|h 108680
|